Kisspeptin and hormone health: what TikTok gets wrong

What did @kimconstableofficial actually say?

Kim Constable argues that hormones are not the root problem for most women, they are the end result. The real upstream controller, she says, is "kisspeptin" (she mispronounces it as "chispeptin" throughout). She describes it as a brain-produced peptide that governs GnRH release, which in turn regulates estrogen, progesterone, and ovulation. Her core argument is that stress, low energy availability, and poor metabolic health suppress kisspeptin signaling, which shuts down reproductive function downstream. She points to hypothalamic amenorrhea and irregular cycles as conditions where this mechanism is now being studied. The framing is that women should stop asking what is wrong with their hormones and start asking what is controlling them.

The claim is not wild. It is also not new. Researchers have been publishing on kisspeptin since the early 2000s. Whether a TikTok audience is getting an accurate version of that science is a different question.

Does the science back this up?

Largely, yes, with some important caveats about what kisspeptin does versus what it can fix. The core biology is solid. Kisspeptin neurons in the hypothalamus are considered primary regulators of GnRH pulsatility, and disrupted kisspeptin signaling has been documented in hypothalamic amenorrhea and polycystic ovarian syndrome.

Seminara et al. (2003, New England Journal of Medicine) identified loss-of-function mutations in the kisspeptin receptor gene as a cause of hypogonadotropic hypogonadism in humans, which put kisspeptin firmly on the map as a reproductive regulator. Subsequent work by Navarro et al. (2009, Journal of Neuroendocrinology) confirmed that kisspeptin neurons integrate metabolic signals, including leptin, ghrelin, and energy status, before deciding whether to fire GnRH pulses. So her statement that the brain integrates "energy availability, body fat, metabolic health and even stress" before activating the reproductive axis is consistent with published neuroscience.

The hypothalamic amenorrhea connection is also real. Gordon et al. (2017, Journal of Clinical Endocrinology and Metabolism) documented suppressed kisspeptin activity in athletes with functional hypothalamic amenorrhea. Clinical trials using kisspeptin analogues to restore GnRH pulsatility are ongoing, though none have reached approved therapeutic status.

What did they get wrong (or right)?

She got the core biology right, but she skipped the complexity that actually matters for women watching this video. She presents kisspeptin as if understanding it gives you a clear intervention pathway. It does not, at least not yet.

First, the mispronunciation. She calls it "chispeptin" throughout the entire video. That is not a minor stylistic issue. Women searching for credible information after watching this will not find what they need because they are searching the wrong word. A creator with a claimed decade of hormone expertise should know how to say the molecule she is discussing.

Second, she implies that identifying suppressed kisspeptin signaling is accessible and actionable for the average woman. In practice, there is no validated consumer-grade test for kisspeptin activity. Plasma kisspeptin levels are difficult to measure accurately even in research settings due to rapid enzymatic degradation (Dhillo et al., 2005, Journal of Clinical Endocrinology and Metabolism). Telling women to "start asking" about kisspeptin without explaining that they cannot currently get a reliable answer is incomplete at best.

Third, she credits her own "research" for the GnRH connection. That is established textbook physiology from peer-reviewed science going back over 20 years. Framing it as personal discovery is misleading about the source of the information.

What should you actually know?

Kisspeptin is a legitimate and important piece of reproductive neuroendocrinology. The biology Constable describes is real. If you are a woman dealing with hypothalamic amenorrhea, irregular cycles linked to undereating or overtraining, or unexplained low reproductive hormone levels, asking your doctor about hypothalamic suppression is a reasonable clinical conversation. That conversation should involve an endocrinologist or reproductive specialist, not a TikTok summary.

Kisspeptin analogues are being studied in clinical trials for conditions including hypothalamic amenorrhea and infertility. Jayasena et al. (2014, Journal of Clinical Investigation) showed that kisspeptin-54 infusion could restore LH pulsatility in women with hypothalamic amenorrhea. This is promising research. It is also not available as a standard of care treatment, and no compounded kisspeptin product has been shown in clinical trials to replicate these outcomes. Anyone selling kisspeptin as a ready-to-use hormone fix is ahead of the evidence.

The broader point, that chronic stress, caloric restriction, and overtraining can suppress the hypothalamic-pituitary-gonadal axis, is well-established and genuinely underappreciated in mainstream women's health conversations. That part of her message has value. The mechanism she describes is real. The implication that you can easily identify and correct it is not supported by current clinical reality.